Pucotenlimab, Lenvatinib, and Temozolomide Combination for Resectable Head and Neck Mucosal Melanoma

This clinical study focuses on a specific type of skin cancer known as head and neck mucosal melanoma that can be removed through surgery. The study explores the use of a combination of drugs, namely pucotenlimab, lenvatinib, and temozolomide, before and after surgery. The main goal is to assess the safety and effectiveness of this drug combination in treating this form of melanoma. The importance of this study lies in its potential to improve treatment options for patients with this condition and to address the current challenges associated with managing resectable head and neck mucosal melanoma. Participants in this study will receive the drug combination as a neoadjuvant therapy, which means it will be administered before surgery to shrink the tumor. After the surgery, the same drug combination will be used as an adjuvant therapy to prevent the cancer from returning. The study measures the results by evaluating the pathological response rate, which includes the complete disappearance of the tumor, near-complete disappearance, partial disappearance, and no response. The potential benefits include improved treatment outcomes, while the risks are being carefully monitored as part of the study's safety evaluation.